triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-17. Anything still debated is marked as such rather than presented as settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
== Clinical implications == Immunisation of mothers against male-specific minor histocompatibility (H-Y) antigens has a pathogenic role in many cases of secondary recurrent miscarriage, that is, recurrent miscarriage in pregnancies succeeding a previous live birth. An example of this effect is that the male:female ratio of children born prior and subsequent to secondary recurrent miscarriage is 1.49 and 0.76 respectively.
By late 2019, disagreements emerged within Pakatan Harapan about Mahathir's planned handover of power to Anwar Ibrahim, eventually culminating in a political crisis in 2020. Mahathir and a faction of the coalition felt that Anwar would be unable to command a parliamentary majority. MPs supporting Anwar demanded a timeframe for Mahathir's resignation and handover of power. In February 2020, MPs opposed to Anwar taking over met and agreed to form a new government. Anwar told the media that he had been "betrayed". Anwar and Mahathir met to clarify the situation, where Mahathir insisted he had no involvement in a new government. Mahathir, refusing to work with UMNO leaders, submitted his resignation to the Agong, Abdullah of Pahang, on 24 February 2020. The Agong appointed him interim prime minister until a replacement could be agreed. BERSATU President Muhyiddin Yassin declared the party's withdrawal from Pakatan Harapan; Mahathir also resigned from the party in response. The next day, Mahathir reported to work as usual in his new role as caretaker prime minister. During his interim premiership, he introduced the 2020 Economic Stimulus Package to counter the economic impact of COVID-19, based on three strategies: mitigating its impact, spurring people-centric economic growth, and promoting quality investments. On 29 February, the Agong appointed Muhyiddin prime minister, determining that he was most likely to be able to hold the support of a majority in parliament.
Abacavir (ABC), sold under the brand name Ziagen among others, is a medication used to treat HIV/AIDS. Similar to other nucleoside analog reverse-transcriptase inhibitors (NRTIs), abacavir is used together with other HIV medications, and is not recommended by itself. It is taken by mouth as a tablet or solution and may be used in children over the age of three months. Abacavir is generally well tolerated. Common side effects include vomiting, insomnia (trouble sleeping), fever, and feeling tired. Other common side effects include loss of appetite, headache, nausea (feeling sick), diarrhea, rash, and lethargy (lack of energy). More severe side effects include hypersensitivity, liver damage, and lactic acidosis. Genetic testing can indicate whether a person is at higher risk of developing hypersensitivity. Symptoms of hypersensitivity include rash, vomiting, and shortness of breath. Abacavir is in the NRTI class of medications, which work by blocking reverse transcriptase, an enzyme needed for HIV virus replication. Within the NRTI class, abacavir is a carbocyclic nucleoside. Abacavir was patented in 1988, and approved for use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. Abacavir is used together with other HIV medications, such as abacavir/lamivudine/zidovudine, abacavir/dolutegravir/lamivudine, and abacavir/lamivudine. The combination abacavir/lamivudine is an essential medicine.
== Adverse effects == The use of clinafloxacin is associated with drug-induced light sensitivity (phototoxicity) and low blood sugar. Diarrhea has also been reported. The phototoxicity with clinafloxacin has been more associated with oral dosing as compared to intravenous dosing, though the studies that described this were subject to confounding by study site (that is, patients that received intravenous clinafloxacin were less mobile, and thereby received less sunlight exposure). The mechanism for clinafloxacin's phototoxicity involves the chlorine atom at position 8. In the presence of ultraviolet light, the chemical structure of clinafloxacin is degraded, resulting in the formation of toxic, reactive oxygen species that can damage cellular structures—including DNA. For this reason clinafloxacin can also be classified as a photocarcinogen (a chemical that can cause light-induced cancer), though the risk of developing cancer in humans taking the medication is small. The mechanism for clinafloxacin's effect on blood glucose is thought to involve stimulation of the pancreatic beta cells, which produce insulin (a hormone that lowers blood glucose levels). The symptoms of clinafloxacin overdose are unknown.
Weighted Companion Cubes are variants of Weighted Storage Cubes that are used in the testing chambers. They are differentiated from regular Storage Cubes with small pink hearts on its external surface, instead of an Aperture Science logo. In Portal, during test chamber 17, Chell is given a Weighted Companion Cube by GLaDOS, told by her that it will be her faithful companion for the duration of the test. Chell must use the Cube to complete the chamber, at which point GLaDOS requires her to incinerate the Cube before being able to progress further. The requirement to incinerate the companion cube originates from test-play of Portal, during which players brought their companion cube with them to later levels, with unexpected impact on game play. Another Companion Cube is seen at the end of the game, standing next to the cake. In Portal 2, redesigned Weighted Companion Cubes appear in test chamber 7 in chapter 2. GLaDOS fizzles two of them at the start of the test to annoy Chell. Chell is given the option to take a Weighted Companion Cube with her at the end of the test, but if Chell does this, GLaDOS fizzles the Companion Cube before Chell can enter the lift leading to the next test chamber. A Companion Cube with the old design, supposedly the one from Portal, appears at the very end of the game, as it is ejected, charred and singed, from the shed (possibly at ground level) shortly after Chell's departure. Companion Cubes are also mentioned a lot in the Ratman dens in Portal. In the Lab Rat comic, Ratman is also accompanied by a Companion Cube, which he imagines talks to him.
Sources: en.wikipedia.org
Regular insulin, also known as neutral insulin or soluble insulin, is a type of short-acting medical insulin. It is used to treat type 1 diabetes, type 2 diabetes, gestational diabetes, and complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used with glucose to treat high blood potassium levels. Typically administered by injection under the skin, it can also be injected into a vein or muscle. Its effects usually begin within one hour and last around four hours. The most common side effect is low blood sugar. Other side effects may include pain or skin changes at the injection sites, low blood potassium, and allergic reactions. It is relatively safe to use during pregnancy for the baby. Regular insulin can be derived from the pancreas of pigs or cows, with human versions created by modifying pig insulin or using recombinant technology. Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922. It is listed on the World Health Organization's List of Essential Medicines. In 2017, it ranked as the 209th most commonly prescribed medication in the United States, with over 2 million prescriptions. There are also versions available that are mixed with longer-acting insulin, such as NPH insulin. In 2020, the combination of human insulin and insulin isophane was the 246th most commonly prescribed medication in the US, with more than 2 million prescriptions. Regular insulin is commonly sold under the name of an insulin product line followed by the letter R.
Nine mobile detachments (Panjin, Liaoning; Shenyang, Liaoning; Bayisingtu, Inner Mongolia; Tianjin; Dingzhou, Hebei; Baoding, Hebei; Jinzhong, Shanxi; Zhengzhou, Henan; Pingliang, Gansu); Three Special Operations detachments (Beijing; Tianjin; Shijiazhuang); Two Transportation detachments (Beijing and Xi’an, Shaanxi); One Engineering/Chemical Defence detachment (Huludao, Liaoning); One Helicopter detachment with 3 Groups
The size of a burn is measured as a percentage of total body surface area (TBSA) affected by partial thickness or full thickness burns. First-degree burns that are only red in color and are not blistering are not included in this estimation. Most burns (70%) involve less than 10% of the TBSA. Unit of measuring burns is VSD as 10% TBSA is equal to 1VSD. There are a number of methods to determine the TBSA, including the Wallace rule of nines, Lund and Browder chart, and estimations based on a person's palm size. The rule of nines is easy to remember but only accurate in people over 16 years of age. More accurate estimates can be made using Lund and Browder charts, which take into account the different proportions of body parts in adults and children. The size of a person's handprint (including the palm and fingers) is approximately 1% of their TBSA.
The quality of a vacuum is indicated by the amount of matter remaining in the system, so that a high quality vacuum is one with very little matter left in it. Vacuum is primarily measured by its absolute pressure, but a complete characterization requires further parameters, such as temperature and chemical composition. One of the most important parameters is the mean free path (MFP) of residual gases, which indicates the average distance that molecules will travel between collisions with each other. As the gas density decreases, the MFP increases, and when the MFP is longer than the chamber, pump, spacecraft, or other objects present, the continuum assumptions of fluid mechanics do not apply. This vacuum state is called high vacuum, and the study of fluid flows in this regime is called particle gas dynamics. The MFP of air at atmospheric pressure is very short, 70 nm, but at 100 mPa (≈10−3 Torr) the MFP of room temperature air is roughly 100 mm, which is on the order of everyday objects such as vacuum tubes. The Crookes radiometer turns when the MFP is larger than the size of the vanes. Vacuum quality is subdivided into ranges according to the technology required to achieve it or measure it. These ranges were defined in ISO 3529-1:2019 as shown in the following table (100 Pa corresponds to 0.75 Torr; Torr is a non-SI unit):
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.